Endurance athletes are especially vulnerable because intense exercise depletes natural glutathione levels, slowing recovery and taxing the immune system
Looking ahead, the future of weight loss treatments may involve: Combination therapies that pair GLP-1 medication with other proven weight loss methods Personalized treatment plans tailored to individual patient needs and characteristics Enhanced patient support systems to promote long-term adherence and sustainable lifestyle changes Advancements in drug delivery methods to improve convenience and accessibility As our understanding of obesity and its underlying mechanisms continues to grow, we can expect to see further innovations in the field of weight loss management

In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraceptive (ethinyl estradiol and norethindrone) (Table 4), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT)
A., Elion, R., Shlipak, M., & Liu, A
In addition, while DAFNE allows flexibility in the foods eaten, healthy eating is advocated in all participants who are not within a normal BMI